company background image
NYXH

Nyxoah ENXTBR:NYXH Stock Report

Last Price

€13.70

Market Cap

€353.4m

7D

-0.1%

1Y

-27.2%

Updated

19 May, 2022

Data

Company Financials +
NYXH fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

NYXH Stock Overview

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.

Nyxoah Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nyxoah
Historical stock prices
Current Share Price€13.70
52 Week High€30.00
52 Week Low€13.32
Beta0
1 Month Change-17.77%
3 Month Change-22.86%
1 Year Change-27.21%
3 Year Changen/a
5 Year Changen/a
Change since IPO-29.74%

Recent News & Updates

Shareholder Returns

NYXHBE Medical EquipmentBE Market
7D-0.1%3.1%-1.3%
1Y-27.2%-13.2%-4.5%

Return vs Industry: NYXH underperformed the Belgian Medical Equipment industry which returned -11.1% over the past year.

Return vs Market: NYXH underperformed the Belgian Market which returned -1.4% over the past year.

Price Volatility

Is NYXH's price volatile compared to industry and market?
NYXH volatility
NYXH Average Weekly Movement6.7%
Medical Equipment Industry Average Movement7.4%
Market Average Movement5.2%
10% most volatile stocks in BE Market7.9%
10% least volatile stocks in BE Market3.1%

Stable Share Price: NYXH is more volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: NYXH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

About the Company

FoundedEmployeesCEOWebsite
2009106Olivier Taelmanhttps://www.nyxoah.com

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah Fundamentals Summary

How do Nyxoah's earnings and revenue compare to its market cap?
NYXH fundamental statistics
Market Cap€353.42m
Earnings (TTM)-€28.65m
Revenue (TTM)€1.33m

266.4x

P/S Ratio

-12.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NYXH income statement (TTM)
Revenue€1.33m
Cost of Revenue€6.36m
Gross Profit-€5.03m
Other Expenses€23.62m
Earnings-€28.65m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 09, 2022

Earnings per share (EPS)-1.11
Gross Margin-379.43%
Net Profit Margin-2,159.08%
Debt/Equity Ratio6.0%

How did NYXH perform over the long term?

See historical performance and comparison

Valuation

Is Nyxoah undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.48x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NYXH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NYXH's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: NYXH is unprofitable, so we can't compare its PE Ratio to the European Medical Equipment industry average.

PE vs Market: NYXH is unprofitable, so we can't compare its PE Ratio to the Belgian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NYXH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NYXH is good value based on its PB Ratio (2.5x) compared to the XE Medical Equipment industry average (3.3x).


Future Growth

How is Nyxoah forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


69.1%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NYXH's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if NYXH's earnings are forecast to grow faster than the Belgian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NYXH's revenue (69.1% per year) is forecast to grow faster than the Belgian market (0.8% per year).

High Growth Revenue: NYXH's revenue (69.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NYXH's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Nyxoah performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-36.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NYXH is currently unprofitable.

Growing Profit Margin: NYXH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NYXH is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.

Accelerating Growth: Unable to compare NYXH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NYXH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.7%).


Return on Equity

High ROE: NYXH has a negative Return on Equity (-20.09%), as it is currently unprofitable.


Financial Health

How is Nyxoah's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NYXH's short term assets (€131.6M) exceed its short term liabilities (€12.6M).

Long Term Liabilities: NYXH's short term assets (€131.6M) exceed its long term liabilities (€10.7M).


Debt to Equity History and Analysis

Debt Level: NYXH has more cash than its total debt.

Reducing Debt: Insufficient data to determine if NYXH's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NYXH has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: NYXH has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 37.4% each year.


Dividend

What is Nyxoah current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NYXH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NYXH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NYXH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NYXH's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NYXH has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Olivier Taelman (49 yo)

2.5yrs

Tenure

€730,533

Compensation

Mr. Olivier Taelman serves as a Vice President of Sales Europe at Autonomic Technologies, Inc. Mr. Olivier Taelman is the Chief Executive Officer at Nyxoah S.A. since November 2019 and serves as its Execut...


CEO Compensation Analysis

Compensation vs Market: Olivier's total compensation ($USD773.46K) is about average for companies of similar size in the Belgian market ($USD732.19K).

Compensation vs Earnings: Olivier's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NYXH's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: NYXH's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.7%.


Top Shareholders

Company Information

Nyxoah S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Nyxoah S.A.
  • Ticker: NYXH
  • Exchange: ENXTBR
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €353.424m
  • Shares outstanding: 25.80m
  • Website: https://www.nyxoah.com

Number of Employees


Location

  • Nyxoah S.A.
  • Rue Edouard Belin 12
  • Mont-Saint-Guibert
  • Walloon Brabant
  • 1435
  • Belgium

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.